Tuesday, May 26, 2020
Home Authors Posts by Editor / Curator

Editor / Curator

246 POSTS 0 COMMENTS
Immunomedics, Biotech Stock Review
Biotech News

Immunomedics (IMMU) $33 | Raising Price Potential to $60. American BriVision...

Editor / Curator -
Organicell
Superbug News

Corona Craziness Continues. Organicell (BPSR) Gains 10-fold or 1000%, in Six...

Editor / Curator -
Superbug News

MRSA: Can Kill Within 24 Hours. Here Are Some Basics.

Editor / Curator -
All News

MRSA: Methicillin (antibiotic) Resistant Staphylococcus Aureus.

Editor / Curator -
Organicell
Infections

Organicell (BPSR) a Triple Since Easter.

Editor / Curator -
video
Stand Down

Stand Down X: Peter Shiff, “We Have Run Out of Road,...

Editor / Curator -
Telehealth

How CoronaVirus Accelerated the Rise of Telemedicine (CNBC).

Editor / Curator -
All News

After FDA authorizes at-home saliva test for Covid-19, startups begin selling...

Editor / Curator -
Biotech Stock Review
All News

Biotech Stock Review Adds One Medical (ONEM) $28.50 to Watchlist.

Editor / Curator -
Stand Down

Stand Down IX: Is the Country Headed Into a Global Depression?...

Editor / Curator -
123...25Page 1 of 25

Latest article

Immunomedics, Biotech Stock Review

Immunomedics (IMMU) $33 | Raising Price Potential to $60. American BriVision (ABVC) $3.00 |...

Biotech News Editor / Curator -
We Are Raising the Price Potential of Immunomedics (IMMU) to $60, Highest on the Street, and Initiating Coverage on Another $3.00 Medical...
Organicell

Corona Craziness Continues. Organicell (BPSR) Gains 10-fold or 1000%, in Six Weeks.

Superbug News Editor / Curator -
Too bad we don't trade for a living! We don't even use real-time quotes, LOL. $0.02 to $0.27, from Easter - what...

MRSA: Can Kill Within 24 Hours. Here Are Some Basics.

Superbug News Editor / Curator -
RESIST THE RESISTANCE: A PRIMER ON ANTIBIOTICS & ANTIBIOTIC RESISTANCE (2013) I was going to write this week about...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: roland@institutionalanalyst.com
© Managed by Revelers.IO Media Group Inc.